UB Paderborn / Katalog / Suche / in CDI

1 – 10 von 10

Sortiert nach

Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF Mutations on Formalin-Fixed, Paraffin-Embedded Tumor Material of Non-Small Cell Lung Carcinoma-Superiority of NGS

Genes chromosomes & cancer, 2013-05, Vol.52 (5), p.503-511

2013

Volltextzugriff (PDF)

Targeted Resequencing Reveals ALK Fusions in Non-Small Cell Lung Carcinomas Detected by FISH, Immunohistochemistry, and Real-Time RT-PCR: A Comparison of Four Methods

BioMed research international, 2013-01, Vol.2013, p.757490-9

2013

Volltextzugriff (PDF)

Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints

Scandinavian journal of gastroenterology, 2010-09, Vol.45 (9), p.1036-1041

2010

Volltextzugriff (PDF)

206 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib

Lung cancer (Amsterdam, Netherlands), 2024-04, Vol.190, p.107767, Article 107767

2024

Volltextzugriff (PDF)

PP01.50 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e25-e26

2024

Volltextzugriff (PDF)

SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4601-TPS4601

2022

Volltextzugriff (PDF)

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic

The Journal of molecular diagnostics : JMD, 2024-01, Vol.26 (1), p.73-84

2024

Volltextzugriff (PDF)

Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients for treatment with osimertinib

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9553-9553

2020

Volltextzugriff (PDF)

Company Profile: Lab21 Ltd

Pharmacogenomics, 2012-10, Vol.13 (13), p.1453-1457

2012

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients

Journal of thoracic oncology, 2014-06, Vol.9 (6), p.886-891

2014

Volltextzugriff (PDF)

1 – 10 von 10

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(10)
Mit Volltextzugriff
(10)

Publikationsform

Artikel
(10)

Sprache

Englisch
(10)
Japanisch
(2)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF Mutations on Formalin-Fixed, Paraffin-Embedded Tumor Material of Non-Small Cell Lung Carcinoma-Superiority of NGS

Targeted Resequencing Reveals ALK Fusions in Non-Small Cell Lung Carcinomas Detected by FISH, Immunohistochemistry, and Real-Time RT-PCR: A Comparison of Four Methods

Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints

206 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib

PP01.50 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib

SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC)

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic

Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients for treatment with osimertinib

Company Profile: Lab21 Ltd

Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients

Suchergebnisse filtern